Shikonin and its derivatives inhibit the epidermal growth factor receptor signaling and synergistically kill glioblastoma cells in combination with erlotinib

International Journal of Cancer

Volumn 137, Issue 6, 2015, Pages 1446-1456

  Zhao, Qiaoli ^a   Kretschmer, Nadine ^b   Bauer, Rudolf ^b   Efferth, Thomas ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b UNIVERSITY OF GRAZ   (Austria)

Author keywords

drug resistance; epidermal growth factor receptor; naphthoquinone; shikonin; synergism; tyrosine kinase inhibitor

Indexed keywords

2 METHYLBUTYRYLALKANNIN; 2 METHYLBUTYRYLSHIKONIN; ACETYLALKANNIN; ACETYLSHIKONIN; ALKANNIN; BETA HYDROXYISOVALERYLALKANNIN; BETA HYDROXYISOVALERYLSHIKONIN; BETA,BETA DIMETHYLACRYLSHIKONIN; DEOXYSHIKONIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; ISOBUTYRYLALKANNIN; ISOBUTYRYLSHIKONIN; ISOVALTRYSHIKONIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHOLIPASE C GAMMA1; PROPIONYLALKANNIN; PROTEIN KINASE B; SHIKONIN; SHIKONIN DERIVATIVE; TERACRYLALKANNIN; UNCLASSIFIED DRUG; ANTHRAQUINONE DERIVATIVE; ANTINEOPLASTIC AGENT; BETA,BETA-DIMETHYLACRYSHIKONIN; EGFR PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE; NAPHTHOQUINONE; QUINAZOLINE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG POTENTIATION; GLIOBLASTOMA; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; METABOLISM; PHOSPHORYLATION; TUMOR CELL LINE;

ANTHRAQUINONES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; DRUG SYNERGISM; GLIOBLASTOMA; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASES; NAPHTHOQUINONES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 84936846894     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29483     Document Type: Article

References (51)

1. Mrugala MM,. Advances and challenges in the treatment of glioblastoma: a clinician's perspective. Discov Med 2013; 15: 221-30.
2. Agnihotri S, Burrell KE, Wolf A, et al., Glioblastoma, a brief review of history, molecular genetics, animal models and novel therapeutic strategies. Arch Immunol Et Ther Exp 2013; 61: 25-41.
3. Taylor TE, Furnari FB, Cavenee WK,. Targeting EGFR for treatment of glioblastoma: molecular basis to overcome resistance. Curr Cancer Drug Targets 2012; 12: 197-209.
4. Hynes NE, Lane HA,. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005; 5: 341-54.
5. Mosesson Y, Yarden Y,. Oncogenic growth factor receptors: implications for signal transduction therapy. Semin Cancer Biol 2004; 14: 262-70.
6. Furnari FB, Fenton T, Bachoo RM, et al., Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 2007; 21: 2683-710.
7. Liu MZ, Yang Y, Wang C, et al., The effect of epidermal growth factor receptor variant III on glioma cell migration by stimulating ERK phosphorylation through the focal adhesion kinase signaling pathway. Arch Biochem Biophys 2010; 502: 89-95.
8. Heimberger AB, Hlatky R, Suki D, et al., Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. Clin Cancer Res 2005; 11: 1462-6.
9. Gan HK, Kaye AH, Luwor RB,. The EGFRvIII variant in glioblastoma multiforme. J Clin Neurosci 2009; 16: 748-54.
10. Hatanpaa KJ, Burma S, Zhao DW, et al., Epidermal growth factor receptor in glioma: signal transduction, neuropathology, imaging, and radioresistance. Neoplasia 2010; 12: 675-84.
11. Karpel-Massler G, Schmidt U, Unterberg A, et al., Therapeutic inhibition of the epidermal growth factor receptor in High-grade gliomas: where do we stand? Mol Cancer Res 2009; 7: 1000-12.
12. Brown PD, Krishnan S, Sarkaria JN, et al., Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: north central cancer treatment group study N0177. J Clin Oncol 2008; 26: 5603-9.
13. Prados MD, Chang SM, Butowski N, et al., Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. J Clin Oncol 2009; 27: 579-84.
14. Zhu JJ, Wong ET,. Personalized medicine for glioblastoma: current challenges and future opportunities. Curr Mol Med 2013; 13: 358-67.
15. Wiench B, Eichhorn T, Paulsen M, et al., Shikonin directly targets mitochondria and causes mitochondrial dysfunction in cancer cells. Evid Based Complement Alternat Med 2012; 2012: 726025.
16. Calonghi N, Pagnotta E, Parolin C, et al., A new EGFR inhibitor induces apoptosis in colon cancer cells. Biochem Biophys Res Commun 2007; 354: 409-13.
17. Hashimoto S, Xu Y, Masuda Y, et al., beta-hydroxyisovalerylshikonin is a novel and potent inhibitor of protein tyrosine kinases. Jpn J Cancer Res 2002; 93: 944-51.
18. Sertel S, Plinkert PK, Efferth T,. Natural products derived from traditional chinese medicine as novel inhibitors of the epidermal growth factor receptor. Comb Chem High Throughput Screen 2010; 13: 849-54.
19. Damianakos H, Kretschmer N, Syklowska-Baranek K, et al., Antimicrobial and cytotoxic isohexenylnaphthazarins from arnebia euchroma (royle) jonst. (boraginaceae) callus and cell suspension culture. Molecules 2012; 17: 14310-22.
20. Kretschmer N, Rinner B, Deutsch AJ, et al., Naphthoquinones from onosma paniculata induce cell-cycle arrest and apoptosis in melanoma cells. J Nat Prod 2012; 75: 865-9.
21. Jones G, Machado J Jr., Merlo A,. Loss of focal adhesion kinase (FAK) inhibits epidermal growth factor receptor-dependent migration and induces aggregation of nh(2)-terminal FAK in the nuclei of apoptotic glioblastoma cells. Cancer Res 2001; 61: 4978-81.
22. Castro F, Dirks WG, Fahnrich S, et al., High-throughput SNP-based authentication of human cell lines. Int J Cancer 2013; 132: 308-14.
23. Buck E, Eyzaguirre A, Brown E, et al., Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors. Mol Cancer Ther 2006; 5: 2676-84.
24. Lee JJ, Kong M, Ayers GD, et al., Interaction index and different methods for determining drug interaction in combination therapy. J Biopharm Stat 2007; 17: 461-80.
25. Zhang W, Peyton M, Xie Y, et al., Histone deacetylase inhibitor romidepsin enhances anti-tumor effect of erlotinib in Non-small cell lung cancer (NSCLC) cell lines. J Thorac Oncol 2009; 4: 161-6.
26. Zhao Q, Zeino M, Eichhorn T, et al., Molecular docking studies of myxobacterial disorazoles and tubulysins to tubulin. J Biosci Med 2013; 3: 37-44.
27. Borisy AA, Elliott PJ, Hurst NW, et al., Systematic discovery of multicomponent therapeutics. Proc Natl Acad Sci USA 2003; 100: 7977-82.
28. Schulte A, Liffers K, Kathagen A, et al., Erlotinib resistance in EGFR-amplified glioblastoma cells is associated with upregulation of EGFRvIII and PI3Kp110delta. Neuro Oncol 2013; 15: 1289-301.
29. Gebhart GF,. Comments on the isobole method for analysis of Drug-interactions. Pain 1992; 51: 381
30. Zhang X, Pickin KA, Bose R, et al., Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface. Nature 2007; 450: 741-4.
31. Newman DJ, Cragg GM,. Natural products as sources of new drugs over the 30 years from 1981 to 2010. J Nat Prod 2012; 75: 311-35.
32. Han W, Xie J, Fang Y, et al., Nec-1 enhances Shikonin-induced apoptosis in leukemia cells by inhibition of RIP-1 and ERK1/2. Int J Mol Sci 2012; 13: 7212-25.
33. Cui XR, Tsukada M, Suzuki N, et al., Comparison of the cytotoxic activities of naturally occurring hydroxyanthraquinones and hydroxynaphthoquinones. Eur J Med Chem 2008; 43: 1206-15.
34. Ahn BZ, Baik kU, Kweon GR, et al., Acylshikonin analogues: synthesis and inhibition of DNA topoisomerase-I. J Med Chem 1995; 38: 1044-7.
35. Lu Q, Liu W, Ding J, et al., Shikonin derivatives: synthesis and inhibition of human telomerase. Bioorg Med Chem Lett 2002; 12: 1375-8.
36. Chen CH, Lin ML, Ong PL, et al., Novel multiple apoptotic mechanism of shikonin in human glioma cells. Ann Surg Oncol 2012; 19: 3097-106.
37. Huang C, Luo Y, Zhao J, et al., Shikonin kills glioma cells through necroptosis mediated by RIP-1. Plos One 2013; 8: e66326
38. Singh F, Gao DY, Lebwohl MG, et al., Shikonin modulates cell proliferation by inhibiting epidermal growth factor receptor signaling in human epidermoid carcinoma cells. Cancer Lett 2003; 200: 115-21.
39. Garcia-Claver A, Lorente M, Mur P, et al., Gene expression changes associated with erlotinib response in glioma cell lines. Eur J Cancer 2013; 49: 1641-53.
40. Yamasaki F, Zhang D, Bartholomeusz C, et al., Sensitivity of breast cancer cells to erlotinib depends on cyclin-dependent kinase 2 activity. Mol Cancer Ther 2007; 6: 2168-77.
41. Glaysher S, Bolton LM, Johnson P, et al., Targeting EGFR and PI3K pathways in ovarian cancer. Br J Cancer 2013; 109: 1786-94.
42. Karpel-Massler G, Westhoff MA, Zhou S, et al., Combined inhibition of HER1/EGFR and RAC1 results in a synergistic antiproliferative effect on established and primary cultured human glioblastoma cells. Mol Cancer Ther 2013; 12: 1783-95.
43. Bijnsdorp IV, Kruyt FA, Fukushima M, et al., Molecular mechanism underlying the synergistic interaction between trifluorothymidine and the epidermal growth factor receptor inhibitor erlotinib in human colorectal cancer cell lines. Cancer Sci 2010; 101: 440-7.
44. Li T, Ling YH, Perez-Soler R,. Tumor dependence on the EGFR signaling pathway expressed by the p-EGFR:p-AKT ratio predicts erlotinib sensitivity in human non-small cell lung cancer (NSCLC) cells expressing wild-type EGFR gene. J Thorac Oncol 2008; 3: 643-7.
45. Klein S, Levitzki A,. Targeting the EGFR and the PKB pathway in cancer. Curr Opin Cell Biol 2009; 21: 185-93.
46. Chen Y, Zheng L, Liu J, et al., Shikonin inhibits prostate cancer cells metastasis by reducing matrix metalloproteinase-2/-9 expression via AKT/mTOR and ROS/ERK1/2 pathways. Int Immunopharmacol 2014; 21: 447-55.
47. Wiench B, Chen YR, Paulsen M, et al., Integration of Different "-omics" technologies identifies inhibition of the IGF1R-Akt-mTOR signaling cascade involved in the cytotoxic effect of shikonin against leukemia cells. Evid Based Complement Alternat Med 2013; 2013: 818709
48. Kanzawa T, Germano IM, Kondo Y, et al., Inhibition of telomerase activity in malignant glioma cells correlates with their sensitivity to temozolomide. Br J Cancer 2003; 89: 922-9.
49. Boehrer S, Galluzzi L, Lainey E, et al., Erlotinib antagonizes constitutive activation of SRC family kinases and mTOR in acute myeloid leukemia. Cell Cycle 2011; 10: 3168-75.
50. Nakaya K, Miyasaka T,. A shikonin derivative, beta-hydroxyisovaleryishikonin, is an ATP-non-competitive inhibitor of protein tyrosine kinases. Anticancer Drugs 2003; 14: 683-93.
51. Efferth T, Koch E,. Complex interactions between phytochemicals. The multi-target therapeutic concept of phytotherapy. Curr Drug Target 2011; 12: 122-32.